SCHEMBL3582859

SCHEMBL3582859

O=C(O)c1ccc(-c2ccccc2)cc1C(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 3/20 0.59
HNF4A P41235 2/20 0.59
DHFR P00374 1/20 0.55
MCL1 Q07820 1/20 0.55
DCLRE1A Q6PJP8 1/20 0.53
DCLRE1B Q9H816 1/20 0.53
ACLY P53396 7/20 0.51
RXRA P19793 2/20 0.50
RXRB P28702 2/20 0.50
LDHA P00338 1/20 0.50
RXRG P48443 1/20 0.50
FABP4 P15090 1/20 0.48
HDAC6 Q9UBN7 1/20 0.47
PTPN1 P18031 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
EPHX2 P34913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31369064 1.00 ACMSD (0.59) ACMSDHNF4ADHFRMCL1DCLRE1A
SCHEMBL940864 0.92 RXRB (0.54) ACMSDHNF4ADHFRMCL1ACLY
SCHEMBL31000476 0.92 RXRB (0.54) ACMSDHNF4ADHFRMCL1ACLY
SCHEMBL27702500 0.91 RXRA (0.49) ACMSDHNF4ADHFRMCL1DCLRE1A
SCHEMBL28566197 0.88 KIF11 (0.50) ACMSDHNF4ADHFRMCL1DCLRE1A
SCHEMBL30131558 0.88 IKBKB (0.56) ACMSDHNF4ADHFRMCL1ACLY
SCHEMBL27633639 0.87 ACMSD (0.58) ACMSDHNF4ADHFRMCL1DCLRE1A
SCHEMBL272323 0.86 RXRA (0.55) ACLYRXRARXRB
SCHEMBL8920290 0.85 RXRA (0.50) ACMSDHNF4ADHFRMCL1RXRA
SCHEMBL29530817 0.85 MCL1 (0.60) ACMSDHNF4AMCL1DCLRE1BACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101068773-A Melanin concentrating hormone antagonists PROCTER & GAMBLE (US) 2007-11-07 CN claimed
US-8772291-B2 Multicyclic compounds and methods of their use LEXICON PHARMACEUTICALS, INC. (US) 2014-07-08 US disclosed
CN-1960969-B Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof LILLY CO ELI 2012-03-28 CN disclosed
US-20100081691-A1 MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. (US) 2010-04-01 US disclosed
CN-101119974-A Amide derivatives as PPAR activators HOFFMANN LA ROCHE (CH) 2008-02-06 CN disclosed
CN-101068773-A Melanin concentrating hormone antagonists PROCTER & GAMBLE (US) 2007-11-07 CN disclosed
CN-1960969-A Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof LILLY CO ELI (US) 2007-05-09 CN disclosed
EP-1444225-A2 PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. Applied Research Systems ARS Holding N.V. (AN) 2004-08-11 EP disclosed
WO-2002102799-A2 PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081691-A1 MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE GRIN2C, CHAT, COMT ACMSD 681/4885HNF4A 2172/4885DHFR 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.